Bio Medica Laboratories IPO Final Day: GMP ₹3 (₹-2)
Well, folks, it’s here – the final day for Bio Medica Laboratories’ SME IPO on the NSE. Today, May 25th, 2026, marks the closing bell for subscriptions, and the numbers are… well, let’s dive in and see what’s happening. It’s been an interesting ride so far, and the last-minute rush, or lack thereof, will tell us a lot.
| Date | GMP | Est. Listing |
|---|---|---|
| 28 May | ₹0 | ₹139 |
| 27 May | +₹3 | ₹142 |
| 26 May | +₹3 | ₹142 |
| 25 May | +₹3 | ₹142 |
| 23 May | +₹3 | ₹142 |
Subscription Status
As of the closing of Day 5, the subscription figures for Bio Medica Laboratories are showing 0x across all categories – Retail, NII (Non-Institutional Investors), and QIB (Qualified Institutional Buyers). This is quite unusual, especially on the closing day. Typically, we’d expect to see some significant movement, particularly in the retail segment, as investors scramble to get their applications in. The absence of any subscription across the board at this stage could indicate a few things. It might mean investors are waiting until the very last minute to apply, a strategy some employ hoping for more clarity or a last-minute surge. However, it could also signal a lack of strong investor interest, which is something to watch closely. For an SME IPO, seeing zero subscription across all categories on closing day is definitely a point of concern for potential investors. It doesn’t give us much to go on regarding market appetite for this particular offering.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 2.92x | |
| NII / HNI | 1.41x | |
| QIB | 15.94x | |
| Total | 2.31x |
| Date | Retail | NII | QIB | Total |
|---|---|---|---|---|
| 25 May | 2.92x | 1.41x | 15.94x | 2.31x |
| 22 May | 1.42x | 0.38x | 15.94x | 1.06x |
| 21 May | 1.09x | 0.03x | 15.94x | 0.72x |
GMP Update
Now, let’s talk Grey Market Premium (GMP). The current GMP for Bio Medica Laboratories stands at ₹3. Yesterday, it was at ₹5. This represents a decrease of ₹2. A shrinking GMP on the closing day isn’t ideal. It suggests that the market sentiment might be cooling off, or that demand isn’t as robust as initially hoped. The expected listing price, based on this GMP and the issue price of ₹132, is around ₹135. While still a modest premium, the downward trend from ₹5 to ₹3 is a signal that seasoned investors would certainly take note of. It’s a subtle indicator, but it often reflects the underlying demand and investor confidence in the IPO’s prospects. This decrease could be a reason why we’re seeing subdued subscription numbers.
Should You Apply?
So, the million-dollar question: should you still consider applying for Bio Medica Laboratories’ IPO on its closing day? It’s a tough call with these current numbers. The complete lack of subscription data, even on Day 5, is a significant red flag. Coupled with a declining GMP, it paints a picture of cautious, or perhaps even hesitant, investor interest. For an SME IPO, where liquidity and initial trading performance are crucial, this isn’t the most confidence-inspiring scenario. Remember, the SEBI advisor always recommends thorough due diligence. You’ll want to look beyond just the GMP and subscription figures. Consider the company’s fundamentals, its business model, and its future prospects. If you’re a risk-averse investor, the current situation might warrant sitting this one out. However, if you’ve done your homework and believe in the long-term potential of Bio Medica Laboratories, a last-minute application might be considered, but it’s certainly a higher-risk proposition. The bottom line is, proceed with extreme caution.